We are an incubator and accelerator driving innovative ideas in clinical diagnostics from discovery to proof-of-concept. Our proprietary approaches are commercialized through either licensing to industry leaders or the formation of focused spin-off ventures with dedicated research and business development teams.

Current focus

  1. finding new biomarkers
and confirming their clinical
and laboratory relevance

  2. using nano and micro-structured surfaces
in biomedicine and pushing
the boundaries of what is possible

  3. In the background, we are building new products that can be distributed in the market due to their unique properties. 

Latest news

GeneSpector today announced a collaborative agreement with Thermo Fisher Scientific EMEA Ltd. (“Thermo Fisher”), a world leader in supplying life sciences solutions and services. More

26/08/2024

Project pipelines

Product / technology
(target/biomarker)
Discovery stageDevelopmentScale-upCommercializationCommercial partner
Proof-of-conceptPre-clinic dataClinical validationCE / IVDRMarket
Sample
Collection
Progress: 100 %Siemens , Viamar
DNA/RNA Extraction Kit
(CE IVD)
Progress: 100 %Immunotech, Siemens
PCR COVID Kits
(CE IVD)
Progress: 100 %Generi Biotech, Siemens
Pregnancy-Related Complications Diagnostics
(RT-PCR / miRNA Biomarker)
Progress: 42 %
Multiple Myeloma Diagnostics
(NGS/Set of Biomarkers)
Progress: 14 %
Severity Predictor
(RT-PCR / mRNA Biomarker)
Progress: 42 %
Kidney Diagnostics
(ELISA/MUC1 Biomarker)
Progress: 70 %Immunotech
MALDI
Plates
Progress: 42 %IQS Group, Affipro
Lab-on-Card
Technology
Progress: 14 %IQS Group

Our team

Our business and scientific teams work hand-in-hand to drive innovative diagnostic solutions from concept to reality. We're proud to accelerate ideas that can truly impact patient care.

Michal Pohludka, CEO & Co-founder

See who's who in our team

Our Partnerships

Academia and Hospitals
Charles UniversityCatrin - Czech Advanced Technology and Research InstituteThomayer University HospitalPalacký University OlomoucFaculty of Science, University of OstravaUniversity of OstravaBIOCEVThird Faculty of Medicine, Charles University in PragueFirst Faculty of Medicine, Charles University in Prague
Business
Generi BiotechImmunotechSPADIAIQS GroupMacromoSiemens HealthineersSarstedtAffiproBeckman CoulterViamar

What's new

GeneSpector Announces Collaborative Agreement with Thermo Fisher Scientific EMEA Ltd. 25/08/24

GeneSpector today announced a collaborative agreement with Thermo Fisher Scientific EMEA Ltd. (“Thermo Fisher”), a world leader in supplying life sciences solutions and services.

Putting rapid clinical results into the hands of patients 18/01/23

The timely and accurate diagnosis of disease is necessary for treatments that maximize the patients’ survival and quality of life. For this, an ever-growing number of disease-related biomarkers is monitored, usually with expensive instruments. These tests may not be accessible at routine doctor’s appointments or even in emergency situations, as samples need to be sent for testing to large centralized laboratories, adding cost and delays of several days or more and the need for repeated visits.

Major breakthrough in the fight against AIDS 18/01/23

Acquired immunodeficiency syndrome, better known under the abbreviation AIDS, represents a spectrum of medical conditions caused by an infection with the human immunodeficiency virus (HIV). HIV is primarily transmitted via unprotected sex and contaminated hypodermic needles and targets white blood cells causing a gradual shutdown of host’s immune system. Such immunocompromised person is susceptible to a wide variety of secondary infections—which would otherwise pose no danger for a healthy individual—leading to the development of AIDS and, eventually, death.

Saving lives months ahead: prediction of risk of pregnancy complications 18/01/23

Complications in pregnancy affect 5 to 10% of women and can not only threaten the life or health of the mother and her child, but also cause irreversible changes in their metabolism and cardiovascular and cerebrovascular systems. However, current methods can only predict them with very limited success, based on the mother’s medical history, i.e., diseases occurring in the family, ultrasound and biochemical examination. Undetected and unmanaged changes can then manifest themselves years later in the form of heart attack, stroke, intellectual disability, diabetes, or metabolic disorders, so early prediction is the key to their successful management or even prevention.

Contact

Do not hesitate
to contact us:

General queries,
investors & partners

info@genespector.com

 

US subsidiary

GeneSpector Innovations USA, Inc.
3500 South Dupont Highway
Dover DE 19901

EU subsidiary

GeneSpector s.r.o.
Petrska 1180/3
110 00 Prague, Czech Republic